Picture of Teleflex Incorporated logo

TFX — Teleflex Incorporated News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Teleflex Q3 revenue slightly beats estimates

((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
    
Overview
    * US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations
    * Adjusted diluted EPS for Q3 rose to $2.63, beating consensus
    * Company repurchased $350 mln in stock since July 1, 2026

    
Outlook
    * Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%
    * Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations
    * Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes

    
Result Drivers
    * SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman
    * TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations
    * MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman

    
Company press release:  ID:nBwvY6jfa 
    
Key Details
 Metric        Beat/Miss     Actual        Consensus
                                           Estimate
 Q3 Revenue    Slight Beat*  $567.78 mln   $566.77 mln
                                           (11
                                           Analysts)
 Q3 Adjusted   Beat          $2.63         $1.90 (12
 EPS                                       Analysts)
 Q3 EPS                      $1.30          
 continuing                                
 operations                                
    *Applies to a deviation of less than 1%; not applicable for per-share numbers.
    
Analyst Coverage
    * The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
    * The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
    * Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87
    * The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

    
Reuters Recommended Reads
    * Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales
    * Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
    * Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength 

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .

    (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Teleflex Incorporated

See all news